Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Discovery | 4 | 2014 | 82 | 1.060 |
Why?
|
| Quantitative Structure-Activity Relationship | 3 | 2011 | 107 | 1.050 |
Why?
|
| Gene Silencing | 2 | 2022 | 151 | 0.890 |
Why?
|
| Models, Molecular | 5 | 2011 | 808 | 0.770 |
Why?
|
| Rare Diseases | 1 | 2020 | 13 | 0.750 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 409 | 0.500 |
Why?
|
| Computer Simulation | 3 | 2011 | 362 | 0.450 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 112 | 0.430 |
Why?
|
| Receptors, Drug | 1 | 2011 | 58 | 0.390 |
Why?
|
| Estrogen Receptor beta | 1 | 2011 | 40 | 0.390 |
Why?
|
| Informatics | 1 | 2011 | 3 | 0.390 |
Why?
|
| Gene Library | 1 | 2011 | 57 | 0.380 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2010 | 19 | 0.360 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2010 | 34 | 0.360 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 75 | 0.360 |
Why?
|
| Drug Design | 1 | 2011 | 162 | 0.350 |
Why?
|
| Apoferritins | 1 | 2009 | 5 | 0.350 |
Why?
|
| Computer Graphics | 1 | 2009 | 17 | 0.350 |
Why?
|
| Anesthetics | 1 | 2009 | 11 | 0.340 |
Why?
|
| User-Computer Interface | 1 | 2009 | 62 | 0.340 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 147 | 0.320 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 71 | 0.310 |
Why?
|
| Computational Biology | 1 | 2010 | 293 | 0.300 |
Why?
|
| Ligands | 3 | 2011 | 349 | 0.260 |
Why?
|
| Hedgehog Proteins | 1 | 2024 | 50 | 0.230 |
Why?
|
| Pyridines | 1 | 2024 | 116 | 0.230 |
Why?
|
| Pyrimidines | 1 | 2024 | 118 | 0.230 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 935 | 0.220 |
Why?
|
| Nucleotides | 1 | 2022 | 36 | 0.220 |
Why?
|
| RNA Interference | 1 | 2022 | 243 | 0.200 |
Why?
|
| Autophagy | 2 | 2020 | 116 | 0.190 |
Why?
|
| PubMed | 1 | 2020 | 4 | 0.190 |
Why?
|
| Fatty Liver | 1 | 2020 | 64 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 204 | 0.170 |
Why?
|
| Oncogenes | 1 | 2018 | 43 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 182 | 0.160 |
Why?
|
| Binding Sites | 2 | 2011 | 651 | 0.160 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1207 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 145 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 172 | 0.150 |
Why?
|
| Models, Biological | 2 | 2011 | 677 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 190 | 0.150 |
Why?
|
| Algorithms | 2 | 2011 | 465 | 0.150 |
Why?
|
| Protein Binding | 2 | 2011 | 972 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 803 | 0.140 |
Why?
|
| Molecular Structure | 2 | 2009 | 492 | 0.140 |
Why?
|
| Humans | 8 | 2024 | 37093 | 0.120 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 28 | 0.120 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 105 | 0.120 |
Why?
|
| Animals | 6 | 2024 | 15081 | 0.110 |
Why?
|
| Artificial Intelligence | 1 | 2011 | 70 | 0.090 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 43 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 83 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 89 | 0.090 |
Why?
|
| Horses | 1 | 2009 | 23 | 0.090 |
Why?
|
| ROC Curve | 1 | 2009 | 138 | 0.080 |
Why?
|
| Molecular Conformation | 1 | 2009 | 152 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 265 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1103 | 0.080 |
Why?
|
| Thymidine Kinase | 1 | 2008 | 7 | 0.080 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2008 | 9 | 0.080 |
Why?
|
| HIV Protease | 1 | 2008 | 21 | 0.080 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2008 | 33 | 0.080 |
Why?
|
| X-Ray Diffraction | 1 | 2008 | 57 | 0.080 |
Why?
|
| Protein Conformation | 1 | 2009 | 389 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2009 | 291 | 0.080 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 409 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 156 | 0.070 |
Why?
|
| Mice | 3 | 2024 | 5913 | 0.070 |
Why?
|
| Time Factors | 1 | 2009 | 1742 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2024 | 61 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2024 | 1908 | 0.050 |
Why?
|
| Cell Survival | 1 | 2024 | 864 | 0.050 |
Why?
|
| Female | 1 | 2020 | 20969 | 0.050 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 37 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2018 | 90 | 0.040 |
Why?
|
| Transfection | 1 | 2020 | 523 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 187 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 2231 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 219 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2018 | 180 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 222 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 356 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1198 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2014 | 65 | 0.030 |
Why?
|
| Apoptosis | 1 | 2018 | 1398 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3483 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 643 | 0.020 |
Why?
|
| Male | 1 | 2020 | 20025 | 0.010 |
Why?
|